Regulated
information - Inside information
Breda, the Netherlands / Ghent, Belgium -
argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology
company developing a deep pipeline of differentiated antibody-based
therapies for the treatment of severe autoimmune diseases and
cancer, announced today the pricing of its public offering in the
United States (the Offering) with anticipated gross proceeds
totalling approximately $231 million from the sale of 4,440,000
American Depository Shares (ADSs), at a price to the public of
$52.00 per ADS. argenx increased the Offering from the initially
filed offering size of $150 million.
All of the ADSs are being offered
by argenx, and each of the ADSs offered represents the right to
receive one ordinary share, nominal value of €0.10 per
share.
argenx has granted the underwriters an option to purchase up to an
additional 666,000 ADSs, representing 15% of the ADSs sold in the
Offering. This option can be exercised during the 30-day period
commencing December 13, 2017. The Offering is expected to close on
December 18, 2017, subject to customary closing
conditions.
argenx's ADSs are currently listed on the Nasdaq Global Select
Market under the symbol "ARGX," and argenx's ordinary shares are
currently listed on Euronext Brussels.
Cowen and Piper Jaffray & Co.
are acting as joint bookrunning managers for the Offering, and JMP
Securities and Wedbush PacGrow are acting as co-managers. Kempen
& Co is argenx's advisor in connection with the Offering.
A registration statement relating
to and describing the terms of the Offering has been filed with,
and was declared effective by, the U.S. Securities and Exchange
Commission (SEC) on December 13, 2017. This registration statement
can be accessed through the SEC's website at.
The Offering is being made only by
means of a prospectus forming part of the effective registration
statement. When available, copies of the final prospectus can be
obtained for free from Cowen and Company, LLC, c/o Broadridge
Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717,
Attn: Prospectus Department, by telephone at (631) 274-2806 or by
fax at (631) 254-7140 or from Piper Jaffray & Co., Attn:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN
55403, or by telephone at (800)747-3924, or by email at
prospectus@pjc.com.
This press release is for
information purposes only and does not constitute, and should not
be construed as, an offer to sell or the solicitation of an offer
to buy or subscribe to any securities, nor shall there be any sale
of securities in any jurisdiction in which such offer, solicitation
or sale is not permitted or to any person or entity to whom it is
unlawful to make such offer, solicitation or sale. Reference is
also made to the restrictions set out in "Important information"
below. This press release is not for publication or distribution,
directly or indirectly, in or into any state or jurisdiction into
which doing so would be unlawful or where a prior registration or
approval is required for such purpose.
About
argenx
argenx is a clinical-stage biotechnology company developing a deep
pipeline of differentiated antibody-based therapies for the
treatment of severe autoimmune diseases and cancer. We are focused
on developing product candidates with the potential to be either
first-in-class against novel targets or best-in-class against
known, but complex, targets in order to treat diseases with a
significant unmet medical need. Our ability to execute on this
focus is enabled by our suite of differentiated technologies. Our
SIMPLE Antibody(TM) Platform, based on the powerful llama immune
system, allows us to exploit novel and complex targets, and our
three antibody engineering technologies are designed to enable us
to expand the therapeutic index of our product
candidates.
www.argenx.com
For further
information, please contact:
Joke Comijn, Corporate
Communications Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@arGEN-X.com
Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com
Forward-looking Statements
The contents of this announcement include
statements that are, or may be deemed to be, "forward-looking
statements." These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
"believes," "estimates," "anticipates," "expects," "intends,"
"may," "will," or "should," and include statements argenx makes
concerning the anticipated closing of the public offering. By their
nature, forward-looking statements involve risks and uncertainties
related to the completion of the Offering on the anticipated terms,
or at all, and readers are cautioned that any such forward-looking
statements are not guarantees of future performance. These risks
and uncertainties include, but are not limited to, market
conditions and the satisfaction of customary closing conditions
related to the Offering. argenx's actual results may differ
materially from those predicted by the forward-looking statements
as a result of various important factors, including argenx's
expectations regarding its the inherent uncertainties associated
with competitive developments, preclinical and clinical trial and
product development activities and regulatory approval
requirements; argenx's reliance on collaborations with third
parties; estimating the commercial potential of argenx's product
candidates; argenx's ability to obtain and maintain protection of
intellectual property for its technologies and drugs; argenx's
limited operating history; and argenx's ability to obtain
additional funding for operations and to complete the development
and commercialization of its product candidates. A further list and
description of these risks, uncertainties and other risks can be
found in argenx's SEC filings and reports, including in the
prospectus related to argenx's U.S. public offering filed with the
SEC pursuant to Rule 424(b) of the Securities Act of 1933, as
amended, as well as subsequent filings and reports filed by argenx
with the SEC. Given these uncertainties, the reader is advised not
to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of
publication of this document. argenx undertakes no obligation to
publicly update or revise the information in this press release,
including any forward-looking statements, except as may be required
by law.
Important information
No public offering will be made and no one has
taken any action that would, or is intended to, permit a public
offering in any country or jurisdiction, other than the United
States, where any such action is required, including in the
European Economic Area. In the European Economic Area, the
transaction to which this press release relates will only be
available to, and will be engaged in only with, qualified investors
within the meaning of Directive 2003/71/EC (together with any
applicable implementing measures in the relevant member state of
the European Economic Area and as amended, including by Directive
2010/73/EU, to the extent implemented in the relevant member
state).
In addition, in
the United Kingdom, the transaction to which this press release
relates will only be available to, and will be engaged in only
with, investment professionals falling within Article 19(5) of the
Financial Services and Markets Act (Financial Promotion) Order
2005, as amended (the Order), persons falling within Article
49(2)(a) to (d) of the Order, and other persons to whom this
announcement may lawfully be communicated (all such persons
together being referred to as "relevant persons"). The securities
referred to herein are only available to, and any invitation, offer
or agreement to subscribe, purchase or otherwise acquire such
securities will be engaged in only with relevant persons. Any
person who is not a relevant person should not act or rely on this
communication or any of its contents.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: argenx SE via Globenewswire
argenx (NASDAQ:ARGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
argenx (NASDAQ:ARGX)
Historical Stock Chart
From Apr 2023 to Apr 2024